Trial Profile

A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 30 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Lung cancer
Focus Therapeutic Use

Most Recent Events

04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
08 Jan 2024 Planned number of patients changed from 50 to 230, Parallel and randomized has been added to trial design, study phase changed to Phase 2/3, number of treatment arms changed from 1 to 2.
08 Jan 2024 Planned End Date changed from 30 Jul 2024 to 30 Jul 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com